Nonviral Delivery

Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA

Lisa Caproni

That's Nice LLC

CRISPR

The Groundbreaking Potential of CRISPR Gene Editing

Olivia Newton-John Cancer Research Institute

CDMO

Innovating and Collaborating to Support Biopharma Beyond the Typical CDMO

Janet Hoogstraate, Ph.D.

NorthX Biologics

RNA

Optimized Residual dsRNA Detection for mRNA Therapeutics

Eunseo (Ency) Lee, Ph.D; Namhyun Kim; Hwanjun Yoon, Ph.D.; Sukhwan Kim; Ahyeon Hwang

Samsung Biologics

Gene Editing

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.

Touchlight

Protein Degradation

PROTACS: Upgrading Small Molecule Inhibitors

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Immuno-Oncology

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Derek Hennecke

Inceptor Bio

Pharma's Almanac

The Evolution and the Future of Pharma

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Cell and Gene Therapy

Realizing the Promise of Cell and Gene Therapy with an Advanced Manufacturing Platform

Shailesh Maingi; Mike Nicholson, Ph.D.

Inceptor Bio

Cell Therapy

Enabling Novel Cell Therapies by Leveraging Established Blood Stem Cell Transplant Infrastructure

Chris McClain

Be The Match BioTherapies

mRNA Therapies

Realizing the Promise of RNA Therapies with Lipid Nanoparticle Delivery

Shiksha Mantri, Ph.D.

MilliporeSigma

Cell and Gene Therapy

Expanding a Comprehensive Platform to Support the Future of Cell and Gene Therapies

David Y. H. Chang, Ph.D.

WuXi Advanced Therapies

COVID-19 Impacts

Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?

Pharma's Almanac

Cell and Gene Therapy

Advanced Therapies: Landscape, the Road Forward, and M&A

Thomas Isett

i.e. Advising